92220-65-0

Basic information

• Product Name: DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I
• Synonyms: DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I;Dichlorotetrakis[2-(2-pyridyl)phenyl]diiridium(III)
• CAS NO: 92220-65-0
• Molecular Formula: C₄₄H₃₂Cl₂Ir₂N₄
• Molecular Weight: 1076.14
• Product Categories: Ir
• Mol File: 92220-65-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I(CAS DataBase Reference)
• NIST Chemistry Reference: DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I(92220-65-0)
• EPA Substance Registry System: DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I(92220-65-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 92220-65-0(Hazardous Substances Data)

Usage

Description

DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I, also known as Dichlorotetrakis[2-(2-pyridyl)phenyl]diiridium(III), is an organoiridium compound that features a central iridium atom surrounded by four 2-(2-pyridinyl)phenyl ligands and two chloride ions. This complex is known for its catalytic properties and its ability to emit light, making it a versatile compound with applications in various fields.

Uses

Used in Catalysis:
DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I is used as a catalyst in various chemical reactions due to its ability to facilitate and speed up the processes. Its unique structure allows it to interact with other molecules effectively, making it a valuable component in the field of catalysis.
Used in Organic Light Emitting Diodes (OLEDs):
DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I is used as a phosphorescent dopant in OLEDs for its light-emitting properties. Its ability to emit light upon excitation makes it a suitable material for creating efficient and bright displays and lighting devices.
Used in Electrochemical Cells:
DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I is used in the synthesis of electrochemical cells, where it plays a crucial role in the generation and storage of electrical energy. Its involvement in these processes contributes to the development of advanced energy storage solutions.
Used in Luminescent Compounds:
DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I is used in the creation of luminescent compounds, which are materials that emit light when excited. Its light-emitting properties make it a valuable component in the development of new luminescent materials for various applications.
Used as a Precursor for OLED Iridium Compounds:
DICHLOROTETRAKIS(2-(2-PYRIDINYL)PHENYL)I serves as a precursor for several OLED Iridium compounds, which are essential for the development of high-performance OLED devices. Its role as a starting material allows for the synthesis of more complex and advanced iridium-based compounds for use in OLED technology.

InChI:InChI=1/4C11H8N.2ClH.2Ir/c4*1-2-6-10(7-3-1)11-8-4-5-9-12-11;;;;/h4*1-6,8-9H;2*1H;;/rC44H34Cl2Ir2N4/c1-5-21-37-33(17-1)41-25-9-13-29-49(41)47(37,38-22-6-2-18-34(38)42-26-10-14-30-50(42)47)45-48(46-47,39-23-7-3-19-35(39)43-27-11-15-31-51(43)48)40-24-8-4-20-36(40)44-28-12-16-32-52(44)48/h1-32,45-46H

Upstream product

• 1008-89-5 2-phenylpyridine 
• 7647-01-0 hydrogenchloride 

Downstream Products

• 1449675-16-4 [Ir(phenylpyridine-H)2(3’-phosphino-2,2’:5’,2’’-terthiophene)-P,S]Cl 
• 1447737-16-7 [Ir(2-phenylpyridine)₂(5-(p-methoxyphenyl)-4,5-dipyrrin)] 
• 1152172-07-0 [Ir(2-phenylpyridine)2-(4,7-diphenyl-1,10-phenanthroline)]Cl 

Relevant articles and documents

Development of Strong Visible-Light-Absorbing Cyclometalated Iridium(III) Complexes for Robust and Efficient Light-Driven Hydrogen Production

Weak light absorption of common Ir(III) complexes (e. g., using phenylpyridine as the ligand) has hindered their applications in photocatalytic hydrogen generation from water as an efficient photosensitizer. To address this issue, a series of cyclometalated Ir(III) complexes (Ir1–Ir5), featuring different electron-donating substituents to enhance the absorptivity, have been synthesized and studied as photosensitizers (PSs) for light-driven hydrogen production from water. Ir6–Ir7 were prepared as fundamental systems for comparisons. Electron donors, including 9-phenylcarbazole, triphenylamine, 4,4′-dimethoxytriphenylamine, 4,4′-di(N-hexylcarbazole)triphenylamine moieties were introduced on 6-(thiophen-2-yl)phenanthridine-based cyclometalating (C^N) ligands to explore the donor effect on the hydrogen evolution performance of these cationic Ir(III) complexes. Remarkably, Ir4 with 4,4′-dimethoxytriphenylamine achieved the highest turn-over number (TON) of 12 300 and initial turnover frequency (TOFi) of 394 h?1, with initial activity (activityi) of 547 000 μmol g?1 h?1 and initial apparent quantum yield (AQYi) of 9.59 %, under the illumination of blue light-emitting diodes (LEDs) for 105 hours, which demonstrated a stable three-component photocatalytic system with high efficiency. The TON (based on n(H2)/n(PSr)) in this study is the highest value reported to date among the similar photocatalytic systems using Ir(III) complexes with Pt nanoparticles as catalyst. The great potential of using triphenylamine-based Ir(III) PSs in boosting photocatalytic performance has also been shown.

Compound and organic electroluminescent device

The invention discloses a compound and application of the compound to preparation of an organic electroluminescent device. The invention also provides the organic electroluminescent device, which comprises the compound. The compound provided by the invention is high in thermal stability, simple in synthesis process, low in the cost for a material purification process, and capable of improving thephotoelectric performance of the organic electroluminescent device.

Cyclometalated Ir(iii) complexes as targeted theranostic anticancer therapeutics: Combining HDAC inhibition with photodynamic therapy

The successful design and anticancer mechanistic studies of a series of cyclometalated Ir(iii) complexes with histone deacetylase inhibitory and photodynamic therapy (PDT) activities are reported. This journal is the Partner Organisations 2014.